Physician profile
Eric Michael Ross
NPI 1629743901
$1,086.22
in general payments reported to CMS, 2019-2025
14 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $225 · 2023: $374 · 2024: $39.82 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $448.07 | 2021-2025 | |
| Novo Nordisk INC | $134.82 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Edwards Lifesciences Corporation | $122.89 | 2023 | |
| Pfizer INC. | $86.81 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.51 | 2022 | |
| Dynavax Technologies Corporation | $30.67 | 2023 | Heplisav-B |
| Alkermes, INC. | $30.28 | 2025 | Vivitrol |
| Glaxosmithkline, LLC. | $27.88 | 2025 | Trelegy Ellipta |
| Shield Therapeutics INC | $24.11 | 2025 | |
| Phathom Pharmaceuticals, INC. | $23.06 | 2024 | Voquezna |
| Lilly USA, LLC | $19.82 | 2025 | Zepbound, Mounjaro |
| Cequr Corporation | $19.82 | 2022 | |
| Dexcom, INC. | $16.76 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.